Diagnosing myocardial iron overload

European Heart Journal

Volumn 22, Issue 23, 2001, Pages 2140-2141

  Hoffbrand, A V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; IRON;

CARDIOMYOPATHY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EDITORIAL; ELECTRON SPIN RESONANCE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HUMAN; IRON CHELATION; IRON OVERLOAD; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT;

CARDIOMYOPATHIES; HUMANS; IRON OVERLOAD; MYOCARDIUM;

EID: 0035215117     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2951     Document Type: Editorial

References (16)

1. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload
2. Continuous subcutaneous administration of deferoxamine in patients with iron overload
3. Survival and causes of death in thalassaemia major
4. Results of long-term iron chelating therapy
5. Prevention of disease by subcutaneous deferoxamine in patients with thalassemia major
6. High incidence of cardiomyopathy in beta thalassaemia patients receiving transfusion and iron chelation: Reversal by intensified chelation
7. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells
8. Serum iron-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1
9. Survival in medically treated patients with homozygous β thalassemia
10. Iron-chelating therapy and the treatment of thalassemia
11. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
12. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major
13. A risk benefit assessment of iron-chelation therapy
14. Deferiprone: A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases
15. Combined therapy with deferiprone and desferrioxamine
16. Desferrioxamine-chelatable iron a component of serum non-transferrin-bound iron, used for assessing chelation therapy